Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …

Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of
chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and …

PURPOSE The need for an individualized management of indolent clinical forms in mantle
cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment …

Purpose: We previously reported a 44% overall response rate (ORR) with the oral BCL-2
inhibitor venetoclax in a phase I study of relapsed/refractory non–Hodgkin lymphoma (NHL) …

Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase
(BTK) inhibitors has led to dramatic improvements in the management of B-cell …

Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and
biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the …

Mantle cell lymphoma (MCL), a rare and aggressive B-cell non-Hodgkin lymphoma, mainly
develops in the lymph node (LN) and creates a protective and immunosuppressive niche …

Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all
NHLs and characterized by overexpression of cyclin D1. The last decade has seen the …